| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T85435 | ||||
| Target Name | Insulin receptor | ||||
| Target Type | Successful |
||||
| Drug Potency against Target | 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol | Drug Info | IC50 = 2250 nM | [528746] | |
| 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol | Drug Info | IC50 = 5150 nM | [528746] | ||
| Insulin-detemir | Drug Info | Afinity = 5 nM | [552749] | ||
| NVP-TAE684 | Drug Info | IC50 = 1200 nM | [528588] | ||
| NVP-AEW541 | Drug Info | IC50 = 140 nM | [530263] | ||
| References | |||||
| Ref 528746 | Eur J Pharmacol. 2007 May 7;562(1-2):1-11. Epub 2007 Feb 3.ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. | ||||
| Ref 528746 | Eur J Pharmacol. 2007 May 7;562(1-2):1-11. Epub 2007 Feb 3.ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. | ||||
| Ref 552749 | NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr Top Med Chem. 2007;7(17):1721-33. | ||||
| Ref 528588 | Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21.Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | ||||
| Ref 530263 | J Med Chem. 2009 Aug 27;52(16):4981-5004.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.